,,ii  #aah? ,,congress  #a/ ,session    
,s4 #ceeg  ,,9 ,,! ,,s5ate ,,( ,,!      
,,unit$ ,,/ates  ,decemb] #ai1 #bjbc,mr4
 ,murphy 7= himself & ,mr4 ,braun7      
introduc$ ! foll[+ bill2 :i* 0 read     
twice & ref]r$ to ! ,committee on       
,heal?1 ,education1 ,labor1 & ,p5sions  
,a ,,bill  ,to require ! ,secret>y (    
,heal? & ,human ,s]vices to prep>e a    
report t outl9es a plan = complet+ a    
review ( approv$ opioid analgesic drugs 
t consid]s ! public heal? effects ( su* 
opioid drugs4  #a4 ,review ( opioid     
drugs & actions ,n lat] ?an "o ye> aft] 
! date ( enactm5t ( ?is ,act1 !         
,secret>y ( ,heal? & ,human ,s]vices    
7ref]r$ to 9 ?is section z ! ,secret>y7 
%all publi% on ! website ( ! ,food &    
,drug ,adm9i/ration 7ref]r$ to 9 ?is    
section z ! ,,fda7 a report t outl9es a 
plan = complet+ a review ( opioid       
analgesic drugs t are approv$ "u section
 #eje ( ! ,f$]al ,food1 ,drug1 &        
,cosmetic ,act 7#ba ,u4,s4,c4 #cee7 t   
consid]s ! public heal? effects ( su*   

opioid drugs z "p ( ! b5efit-risk       
assessm5t1 & t addresses ! activities ( 
! ,,fda t relate to increas+ !          
developm5t ( non-addictive m$ical       
products int5d$ to treat pa9 or         
addiction4 ,su* report %all include--   
7#a7 an opportunity = public input      
conc]n+ ! regulation by ! ,,fda ( opioid
 analgesic drugs1 includ+ sci5tific     
evid5ce t relates to conditions ( use1  
safety1 or b5efit-risk assessm5t        
7includ+ consid]ation ( ! public heal?  
effects7 ( su* opioid drugs2  7#b7 an   
update on ! actions tak5 by ! ,,fda to  
review ! effectiv5ess1 safety1          
b5efit-risk pr(ile 7:i* may include     
public heal? effects71 & use ( approv$  
opioid analgesic drugs2  7#c7 a timel9e 
= an assessm5t ( ! pot5tial ne$1 z      
appropriate1 = label+ *anges1 revis$ or 
additional po/m>ket+ requirem5ts1       
en=cem5t actions1 or )drawals = opioid  
analgesic drugs2  7#d7 an ov]view ( !   
/eps t ! ,,fda has tak5 to support !    
developm5t & approval ( non-addictive   

m$ical products int5d$ to treat pa9 or  
addiction1 & actions plann$ to fur!r    
support ! developm5t & approval ( su*   
products2 &  7#e7 an ov]view ( !        
consid]ation by ! ,,fda ( cl9ical trial 
me?odologies = analgesic drugs1 includ+ 
! enri*$ enrollm5t r&omiz$ )drawal      
me?odology1 & ! b5efits & drawbacks     
associat$ ) diff]5t trial me?odologies =
 su* drugs1 incorporat+ any public input
 receiv$ "u p>agraph 7#a74